Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — Juli 2018

Planlagt Fastgjort Låst Flyttet Genmab
1.3k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • Legolas23L Offline
    Legolas23L Offline
    Legolas23
    wrote on sidst redigeret af
    #420

    @Bulder ? @Sukkeralf ? @Solsen ?

    1 Reply Last reply
    0
    • G Offline
      G Offline
      gentogen
      wrote on sidst redigeret af
      #421

      Det hedder, at "The PRAC is responsible for assessing all aspects of risk management of human medicines" , så umiddelbart ville jeg gætte på, at det lige passer med tidsplanen til næste CHMP i slutningen af juli

      1 Reply Last reply
      0
      • G Offline
        G Offline
        gentogen
        wrote on sidst redigeret af
        #422

        og at de altså reelt afgør det.

        1 Reply Last reply
        0
        • M Offline
          M Offline
          mobbyduck1
          wrote on sidst redigeret af
          #423

          men det tager stadig 67 dage til approval derfra ikke??

          1 Reply Last reply
          0
          • StockBullS Offline
            StockBullS Offline
            StockBull
            wrote on sidst redigeret af
            #424

            Ser ud til shorterne er begyndt at reducere lidt: April snit 4.25% shortet. Maj 4.14%, Juni 3.84%

            1 Reply Last reply
            0
            • S Offline
              S Offline
              Sukkeralf
              wrote on sidst redigeret af
              #425

              Mobby - jo ca 2 måneder

              1 Reply Last reply
              0
              • BulderB Offline
                BulderB Offline
                Bulder
                wrote on sidst redigeret af
                #426

                Mest sandsynligt at hvis PRAC ingen indvendinger har, så kommer det på CHMPs næste møde, og i tilfælde af anbefaling, EU-godkendelse 60 dage senere.

                1 Reply Last reply
                0
                • M Offline
                  M Offline
                  mobbyduck1
                  wrote on sidst redigeret af
                  #427

                  så vi snakker sept/Okt i bedste fald?

                  1 Reply Last reply
                  0
                  • BulderB Offline
                    BulderB Offline
                    Bulder
                    wrote on sidst redigeret af
                    #428

                    Ja slutningen af september. Men det reelle er jo CHMP's anbefaling, som så gerne skulle komme d. 27. ds. EU-godkendelsen er kun formel. Men det tager 60 dage at nå rundt i medlemslandene, som hver især skal godkende.

                    1 Reply Last reply
                    0
                    • BulderB Offline
                      BulderB Offline
                      Bulder
                      wrote on sidst redigeret af
                      #429

                      I øvrigt udsender PRAC highlights på fredag. Kan være at der står noget om, hvad de indstiller til CHMP.

                      1 Reply Last reply
                      0
                      • JørgenVarnæsJ Offline
                        JørgenVarnæsJ Offline
                        JørgenVarnæs
                        wrote on sidst redigeret af
                        #430

                        Tak Bulder. Det er også mit indtryk, at ema ikke fraviger deres procedurer for noget som helst. Når nu klokken blev stoppet på processen, så kan man ikke slippe billigere end med en måneds forsinkelse.

                        1 Reply Last reply
                        0
                        • B Offline
                          B Offline
                          bibob
                          wrote on sidst redigeret af
                          #431

                          God morgen. 🙂

                          1 Reply Last reply
                          0
                          • T Offline
                            T Offline
                            transalp
                            wrote on sidst redigeret af
                            #432

                            Go morgen:)

                            1 Reply Last reply
                            0
                            • Helge_LarsenPI-redaktørH Offline
                              Helge_LarsenPI-redaktørH Offline
                              Helge_LarsenPI-redaktør
                              wrote on sidst redigeret af
                              #433

                              God morgen. 🙂

                              1 Reply Last reply
                              0
                              • P Offline
                                P Offline
                                Plimsoller
                                wrote on sidst redigeret af
                                #434

                                God morgen 🙂

                                1 Reply Last reply
                                0
                                • S Offline
                                  S Offline
                                  saltpeter
                                  wrote on sidst redigeret af
                                  #435

                                  July 12, 2018 5:57 AM UTC
                                  Genmab Enters Strategic Partnership with Immatics to Discover and Develop Next Generation Bispecific Cancer Immunotherapies

                                  1 Reply Last reply
                                  0
                                  • S Offline
                                    S Offline
                                    saltpeter
                                    wrote on sidst redigeret af
                                    #436

                                    Genmab gains exclusive access to multiple novel proprietary tumor targets identified by Immatics Biotechnologies’ XPRESIDENT® technology
                                    Creation of novel immuno-oncology drugs combining Genmab and Immatics’ proprietary technologies
                                    Genmab responsible for development, manufacturing and commercialization worldwide
                                    Immatics to receive upfront payment of USD 54 million from Genmab

                                    1 Reply Last reply
                                    0
                                    • S Offline
                                      S Offline
                                      saltpeter
                                      wrote on sidst redigeret af
                                      #437

                                      The deal strengthens Genmab’s position in immuno-oncology by combining Genmab's proprietary technologies and antibody know-how with Immatics' XPRESIDENT® targets and T-cell receptor (TCR) capabilities. Genmab will receive an exclusive license to three proprietary targets from Immatics, with an option to license up to two additional targets at predetermined economics. The companies will conduct joint research, funded by Genmab, on multiple antibody and/or TCR-based bispecific therapeutic product

                                      1 Reply Last reply
                                      0
                                      • S Offline
                                        S Offline
                                        saltpeter
                                        wrote on sidst redigeret af
                                        #438

                                        Genmab may elect to progress any resulting product candidates, and will be responsible for development, manufacturing and worldwide commercialization. For any products that are commercialized by Genmab, Immatics will have an option to limited co-promotion efforts in selected countries in the EU.

                                        1 Reply Last reply
                                        0
                                        • S Offline
                                          S Offline
                                          saltpeter
                                          wrote on sidst redigeret af
                                          #439

                                          This collaboration with Immatics gives us the opportunity to combine our unique technologies and expertise to create differentiated novel next-generation therapies. We very much look forward to this exciting partnership in the field of cancer immunotherapy,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger